{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:41:02Z","timestamp":1775576462554,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12185-025-04039-4","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T16:48:40Z","timestamp":1753721320000},"page":"759-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of post-transplant lymphoproliferative disorders in kidney transplant recipients: a single-center retrospective analysis"],"prefix":"10.1007","volume":"122","author":[{"given":"Futoshi","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9256-609X","authenticated-orcid":false,"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otoya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Taya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"4039_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","volume":"12","author":"S Caillard","year":"2012","unstructured":"Caillard S, Lamy F, Quelen C, Dantal J, Lebranchu Y, Lang P, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant. 2012;12:682\u201393.","journal-title":"Am J Transplant"},{"key":"4039_CR2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/TP.0b013e318270bc7b","volume":"94","author":"MS Sampaio","year":"2012","unstructured":"Sampaio MS, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. national transplant database. Transplantation. 2012;94:990\u20138.","journal-title":"Transplantation"},{"key":"4039_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bmt.2013.96","volume":"49","author":"L Rasche","year":"2014","unstructured":"Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 2014;49:163\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"4039_CR4","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/ajt.12211","volume":"13","author":"AM Evens","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers A, Jagadeesh D, Smith S, Morschhauser F, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13:1512\u201322.","journal-title":"Am J Transplant"},{"key":"4039_CR5","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217\u201327.","journal-title":"Lancet Haematol"},{"key":"4039_CR6","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"4039_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","volume":"31","author":"S Caillard","year":"2013","unstructured":"Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;31:1302\u20139.","journal-title":"J Clin Oncol"},{"key":"4039_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","volume":"19","author":"C Soussain","year":"2001","unstructured":"Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19:742\u20139.","journal-title":"J Clin Oncol"},{"key":"4039_CR9","doi-asserted-by":"publisher","first-page":"33849","DOI":"10.18632\/oncotarget.5292","volume":"6","author":"GM Crane","year":"2015","unstructured":"Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6:33849.","journal-title":"Oncotarget"},{"key":"4039_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.24834","volume":"116","author":"R Cavaliere","year":"2010","unstructured":"Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an international primary central nervous system lymphoma collaborative group report. Cancer. 2010;116:863\u201370.","journal-title":"Cancer"},{"key":"4039_CR11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-021-04548-2","volume":"100","author":"H Zimmermann","year":"2021","unstructured":"Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RM, et al. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Ann Hematol. 2021;100:2043\u201350.","journal-title":"Ann Hematol"},{"key":"4039_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"JL Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for. CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466\u20138.","journal-title":"Blood"},{"key":"4039_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","volume":"83","author":"M Holdhoff","year":"2014","unstructured":"Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83:235\u20139.","journal-title":"Neurology"},{"key":"4039_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11060-012-0891-7","volume":"109","author":"T Birnbaum","year":"2012","unstructured":"Birnbaum T, Stadler EA, von Baumgarten L, Straube A. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol. 2012;109:285\u201391.","journal-title":"J Neurooncol"},{"issue":"3","key":"4039_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","volume":"8","author":"Z Al-Mansour","year":"2013","unstructured":"Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173\u201383.","journal-title":"Curr Hematol Malig Rep"},{"key":"4039_CR16","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","volume":"75","author":"M Majewski","year":"2003","unstructured":"Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75:1710\u20137.","journal-title":"Transplantation"},{"key":"4039_CR17","doi-asserted-by":"publisher","first-page":"i27","DOI":"10.1093\/ndt\/gfm088","volume":"22","author":"J Pascual","year":"2007","unstructured":"Pascual J. Post-transplant lymphoproliferative disorder\u2014the potential of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22:i27\u201335.","journal-title":"Nephrol Dial Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04039-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:37:11Z","timestamp":1761770231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04039-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4039"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04039-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.K. received honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Eisai, Chugai, Genmab, Gilead Sciences, Janssen, Sanofi, Asahi KASEI Pharma, Meiji Seika Pharma, Nippon Shinyaku, Ono, Otsuka Pharma, Pfizer, SymBio, and Takeda. K.Y. received honoraria from AbbVie and Nippon Shinyaku. S.T. received honoraria from AbbVie, Amgen, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Asahi KASEI Pharma, Otsuka Pharma, Novartis, Pfizer, MSD, Astellas Pharma, Kyowa Kirin, Chugai, Nippon Shinyaku, Sumitomo Pharma, and Takeda. H.Y. received honoraria from Chugai, Novartis, Janssen, Takeda, AstraZeneca, Otsuka, Astellas, CSL Behring, JCR Pharma, MSD, Sumitomo Pharma, and Asahi KASEI Pharma. N.U. received grants from Chugai, Fuji Pharma, Sumitomo Pharma, Nippon Boehringer Ingelheim, and JCR Pharma; and honoraria from Chugai, Novartis, AbbVie, Kyowa Kirin, Takeda, MSD, AstraZeneca, Nippon Shinyaku, Daiichi Sankyo, CSL Behring, SymBio, Otsuka, Astellas, and Asahi KASEI Pharma. T.W. received honoraria from Chugai, Novartis, AbbVie, Alexionpharma, Amgen, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Janssen, Meiji Seika Pharma, Mundi Pharma, Nihonkayaku, Ono, Pfizer, Sanofi, Kyowa Kirin, Takeda, AstraZeneca, Daiichi Sankyo, SymBio, Otsuka, Astellas, and Asahi KASEI Pharma. G.Y. received honoraria from AstraZeneca, Chugai, Genmab, Janssen, Meiji Seika Pharma, Mundipharma, Nihonkayaku, Novartis, Bristol Myers Squibb, Ono, Pfizer, Daiichi-Sankyo, Eisai, Sanofi, and Takeda. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the insti- tutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study. The study was approved by the Institutional Review Board of Toranomon Hospital (1710-H).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}